TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04422496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC96719
Description: single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study.
Study: NCT03083509

Intervention type: OTHER
Group type: OTHER
Intervention: Simulated Team sport protocol
Description: A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
Study: NCT03395275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Tests
Description: Three testing modalities will be utilized for this study:~1. Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~2. Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~3. Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results.
Study: NCT04326738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: N group received corresponding intravenous normal saline of1ml·kg-1 .
Study: NCT03395275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surveys
Description: surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
Study: NCT03579524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
Study: NCT05504122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inguinal hernia repair
Description: Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: inguinal hernia repair
Description: Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
Study: NCT03448211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-toluenesulfonamide Injection (PTS)
Description: Intratumoral injection
Study: NCT02652221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Imaging
Description: ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
Study: NCT01877304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKITA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKITA
Study: NCT02095106

Intervention type: DEVICE
Group type: OTHER
Intervention: Waterproof Cast

Intervention type: DEVICE
Group type: OTHER
Intervention: Waterproof Cast

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional cast

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional cast
Study: NCT03198754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEI Experimental Light
Description: Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
Study: NCT02546323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20mg tablets, orally once daily for the duration of the 104-week treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
Study: NCT02874729

Intervention type: PROCEDURE
Intervention: Venesection
Description: Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.

Intervention type: PROCEDURE
Intervention: Venesection
Description: Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.

Intervention type: PROCEDURE
Intervention: Urine collection
Description: Urine will be collected in appropriate sterile holders provided.
Study: NCT03198754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Light
Description: Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
Study: NCT02307071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly Kit Arnold
Description: Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
Study: NCT02874729

Intervention type: PROCEDURE
Intervention: Urine collection
Description: Urine will be collected in appropriate sterile holders provided.

Intervention type: PROCEDURE
Intervention: Sputum collection
Description: Saliva will be collected in appropriate sterile holders provided.

Intervention type: PROCEDURE
Intervention: Sputum collection
Description: Saliva will be collected in appropriate sterile holders provided.

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
Study: NCT02578082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: A single inhaled dose of TD 4208 (175 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: A single inhaled dose of TD 4208 (175 mcg)
Study: NCT01083602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT00672997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004%/Timolol 0.5% ophthalmic solution
Study: NCT02299063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Study: NCT05692778

Intervention type: OTHER
Intervention: Patients being foot examined by using an eHealth tool
Description: Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool

Intervention type: OTHER
Intervention: Patients being foot examined in traditional manner
Description: Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
Study: NCT01211093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High frequency whole body vibration
Description: 1 single session (10 minutes) of whole body vibration therapy at 30 Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency whole body vibration
Description: 1 single session of whole body vibration therapy at 20 Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 1 single session of standing on the vibration platform, with no vibration signals delivered.
Study: NCT02957136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid respiratory pathogen nucleic acid amplification test
Description: Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
Study: NCT04444258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of computer aided virtual reality glasses
Description: Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching fetal development theoretically
Description: Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
Study: NCT00405535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04260334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Education
Description: The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.
Study: NCT03976115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Oral
Study: NCT01428518

Intervention type: DRUG
Intervention: Lamotrigine tablets
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Study: NCT02082145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
Study: NCT01794481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET)
Description: If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique.
Study: NCT02143193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin Contact
Study: NCT04069741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: A website that contains information about de Quervain's tenosynovitis and the options for treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: A website that contains information about de Quervain's tenosynovitis and the options for treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: A website that contains information about de Quervain's tenosynovitis and the options for treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Toolkit for de Quervain's
Description: A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
Study: NCT03594487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMP30 Donor Stool
Description: FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool
Description: Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observational Control
Description: Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
Study: NCT01841996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1111 solution
Description: Once a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Once a day for 28 days
Study: NCT01999192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tregalizumab
Description: humanized anti-CD4 mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tregalizumab
Description: humanized anti-CD4 mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tregalizumab
Description: humanized anti-CD4 mAb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical end formulation buffer
Study: NCT03483948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: HMPL-523 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine Injection
Study: NCT03942081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulcer Measurement Software
Description: Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
Study: NCT02841787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for late life depression
Study: NCT01651468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HEMOFIX
Description: unique complex herbal mixture
Study: NCT02986269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia across LMA
Description: general anesthesia across LMA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia across LMA
Description: general anesthesia across LMA
Study: NCT04497714

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic image collection
Description: Ultrasonic image collection,consist of three static images and one dynamic image

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic image collection
Description: Ultrasonic image collection,consist of three static images and one dynamic image

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic image collection
Description: Ultrasonic image collection,consist of three static images and one dynamic image

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic image collection
Description: Ultrasonic image collection,consist of three static images and one dynamic image
Study: NCT02497105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Dietary
Study: NCT01127919

Intervention type: BEHAVIORAL
Intervention: Aerobic Exercise Training
Description: 40 minutes, 3 times a week for 35 weeks.

Intervention type: BEHAVIORAL
Intervention: Aerobic Exercise Training
Description: 40 minutes, 3 times a week for 35 weeks.

Intervention type: OTHER
Intervention: Cognitive Component
Description: Provide general information about health and fitness

Intervention type: OTHER
Intervention: Cognitive Component
Description: Provide general information about health and fitness
Study: NCT00969423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5mm videoscope
Description: use of 5mm videoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10mm videoscope
Description: use of 10mm videoscope
Study: NCT00718315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fusidic acid [Verutex]
Description: topical, daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin [Eritex]
Description: topical, daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisiogel
Description: topical, daily for 30 days
Study: NCT02384421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive DBS (Activa PC+S Neurostimulator)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous DBS (Activa PC+S Neurostimulator)
Study: NCT02146157

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herb and mineral combination product
Description: herb and mineral product containing cinnamon, turmeric and holy basil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
Study: NCT01935388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common canister
Description: Drug administration via a shared canister with a standardized cleaning protocol.
Study: NCT02271880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication as usual
Description: Physicians will prescribe medication as usual to the adolescent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication as usual
Description: Physicians will prescribe medication as usual to the adolescent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STAR
Description: Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.